Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average rating of “Buy” from the twenty-one ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $133.00.
Several research analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, February 8th. BMO Capital Markets decreased their price objective on Alnylam Pharmaceuticals to $106.00 and set an “outperform” rating on the stock in a research note on Friday, February 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 7th. ValuEngine downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. Finally, UBS Group assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 23rd. They issued a “neutral” rating and a $87.00 price objective on the stock.
Get Alnylam Pharmaceuticals alerts: ALNY stock traded up $0.50 during trading on Friday, reaching $83.53. The stock had a trading volume of 540,470 shares, compared to its average volume of 897,041. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $153.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.96 and a current ratio of 11.05. The company has a market cap of $8.45 billion, a price-to-earnings ratio of -11.03 and a beta of 2.54.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 7th. The biopharmaceutical company reported ($2.09) EPS for the quarter, topping the consensus estimate of ($2.27) by $0.18. Alnylam Pharmaceuticals had a negative return on equity of 48.34% and a negative net margin of 1,016.58%. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $18.03 million. During the same quarter last year, the company earned ($1.20) earnings per share. The business’s revenue for the quarter was down 44.6% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals will post -8.99 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the stock. Fosun International Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $3,288,000. Advisors Asset Management Inc. raised its stake in Alnylam Pharmaceuticals by 15.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 17,001 shares of the biopharmaceutical company’s stock valued at $1,674,000 after purchasing an additional 2,298 shares during the period. Gateway Investment Advisers LLC raised its stake in Alnylam Pharmaceuticals by 17.3% during the 4th quarter. Gateway Investment Advisers LLC now owns 4,531 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 667 shares during the period. Baillie Gifford & Co. raised its stake in Alnylam Pharmaceuticals by 5.5% during the 3rd quarter. Baillie Gifford & Co. now owns 4,462,826 shares of the biopharmaceutical company’s stock valued at $390,587,000 after purchasing an additional 230,945 shares during the period. Finally, Northern Trust Corp raised its stake in Alnylam Pharmaceuticals by 4.4% during the 2nd quarter. Northern Trust Corp now owns 492,768 shares of the biopharmaceutical company’s stock valued at $48,533,000 after purchasing an additional 20,992 shares during the period. 88.42% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Read More: How does inflation affect different investments?
Receive News & Ratings for Alnylam Pharmaceuticals analysts' ratings for Alnylam Pharmaceuticals and related companies daily email newsletter .
